Peregrine Capital Management LLC Sells 63,974 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Peregrine Capital Management LLC lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 32.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 135,678 shares of the specialty pharmaceutical company’s stock after selling 63,974 shares during the quarter. Peregrine Capital Management LLC owned 0.25% of Supernus Pharmaceuticals worth $4,906,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of SUPN. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 352 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after purchasing an additional 560 shares in the last quarter. Rhumbline Advisers lifted its holdings in Supernus Pharmaceuticals by 0.5% during the 4th quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company’s stock worth $6,236,000 after purchasing an additional 800 shares in the last quarter. Assetmark Inc. lifted its holdings in Supernus Pharmaceuticals by 2.8% during the 3rd quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after purchasing an additional 908 shares in the last quarter. Finally, KBC Group NV lifted its holdings in Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 929 shares in the last quarter.

Supernus Pharmaceuticals Stock Down 15.7 %

NASDAQ:SUPN opened at $33.52 on Thursday. The business’s 50-day moving average price is $37.58 and its two-hundred day moving average price is $35.27. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The stock has a market cap of $1.85 billion, a P/E ratio of 31.33 and a beta of 0.90.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald cut Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $57.00 to $36.00 in a report on Wednesday.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.